We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
- Authors
Carrasco, Raquel; Ingelmo-Torres, Mercedes; Trullas, Ramón; Roldán, Fiorella L.; Rodríguez-Carunchio, Leonardo; Juez, Lourdes; Sureda, Joan; Alcaraz, Antonio; Mengual, Lourdes; Izquierdo, Laura
- Abstract
Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were prospectively included. Blood samples from these patients were collected at different follow-up time points. Two specific mutations (TERT c.1-124C>T and ATM c.1236-2A>T) were analyzed in the patients' plasma samples by droplet digital PCR to determine their ctDNA status. During a median follow-up of 21 months, 24% of patients progressed in a median of six months. ctDNA status was identified as a prognostic biomarker of tumor progression before RC and 4 and 12 months later (HR 6.774, HR 3.673, and HR 30.865, respectively; p < 0.05). Lastly, dynamic changes in ctDNA status between baseline and four months later were significantly associated with patient outcomes (p = 0.045). In conclusion, longitudinal ctDNA analysis using a tumor-agnostic approach is a potential tool for monitoring MIBC patients after RC. The implementation of this testing in a clinical setting could improve disease management and patients' outcomes.
- Subjects
CIRCULATING tumor DNA; CANCER invasiveness; BLADDER cancer; DISEASE management; PATIENT monitoring; CANCER patients
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 23, p16578
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms242316578